2018. Targeting OX40 With GBR 830, An OX40 Antagonist, Inhibits T Cell-Mediated Pathological Responses. SKIN The Journal of Cutaneous Medicine. 2, (Dec. 2018), S62. DOI:https://doi.org/10.25251/skin.2.62.